Scholarlink

<p>We investigated the metabolomic profile of Kawasaki disease(KD) and its association with the development of coronary artery aneurysms (CAA) and resistance to intravenous immunoglobulin(IVIG) therapy. Metabolomic profiling was performed on 26 patients with KD. A total of 44 metabolites—including 12 amino acids, L-carnitine, and 31 acylcarnitines—were analyzed using liquid chromatography-tandem mass spectrometry (LC–MS/MS) after IVIG administration. Methylglutarylcarnitine, a medium-chain acylcarnitine, was identified as a differentially expressed metabolite in KD patients with CAA. Additionally, C2, C3, C14, C16, C16OH, C18:2, and C18:2OH were differentially expressed between IVIG-resistant and IVIG-responsive patients. Pathway analysis using the KEGG database revealed that arginine biosynthesis and alanine, aspartate, and glutamate metabolism were among the most affected pathways in KD patients with CAA. This study demonstrated several differentially expressed metabolites in KD patients with CAA and IVIG resistance. These findings provide new insights into the metabolic pathways underlying KD complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolomic Profiling for Predicting Coronary Artery Aneurysms and IVIG Resistance in Kawasaki Disease- An Exploratory Study

  • 期刊论文

  • 发表日期：

    2025年7月18日

查看全文
  • Zahra Amirsardari,
  • Ehsan Aghaei Moghadam,
  • Ali Mohebbi,
  • Vassilios Fanos,
  • Aryan Ayati,
  • Michael A. Portman,
  • Fatemeh Tahghighi,
  • Vahid Ziaee

摘要

We investigated the metabolomic profile of Kawasaki disease(KD) and its association with the development of coronary artery aneurysms (CAA) and resistance to intravenous immunoglobulin(IVIG) therapy. Metabolomic profiling was performed on 26 patients with KD. A total of 44 metabolites—including 12 amino acids, L-carnitine, and 31 acylcarnitines—were analyzed using liquid chromatography-tandem mass spectrometry (LC–MS/MS) after IVIG administration. Methylglutarylcarnitine, a medium-chain acylcarnitine, was identified as a differentially expressed metabolite in KD patients with CAA. Additionally, C2, C3, C14, C16, C16OH, C18:2, and C18:2OH were differentially expressed between IVIG-resistant and IVIG-responsive patients. Pathway analysis using the KEGG database revealed that arginine biosynthesis and alanine, aspartate, and glutamate metabolism were among the most affected pathways in KD patients with CAA. This study demonstrated several differentially expressed metabolites in KD patients with CAA and IVIG resistance. These findings provide new insights into the metabolic pathways underlying KD complications.